Table 3.
Drugs associated with gemcitabine in clinical trials.
| Drug | Mechanism of Action | NCT |
|---|---|---|
| Flicatuzumab | Anti-HGF IgG1 mAb | NCT03316599 |
| Durvalumab | Anti-PD-L1 mAb | NCT03572400 |
| Paricalcitol | Vitamin D effects | NCT03520790 |
| CPI-613 (Devimistat) | Targets the pyruvate dehydrogenase complex | NCT03435289 |
| Napabucasin | STAT3 inhibitor | NCT03721744 |
| Gimatecan | Topoisomerase I inhibitor | NCT04571489 |
| SHR-1210 | Anti-PD1 mAb | NCT04181645 |
| Abraxane | Protein bound paclitaxel with similar effects to paclitaxel | NCT01693276 |
| Ubidicarenone (BPM- 31510) [622] | Anti-Warburg switch in cancer cell metabolism and activation of apoptosis | NCT02650804 |
| Fruquintinib | VEGFR1, 2, and 3 inhibitor | NCT05168527 |
| Pamrevlumab [623] | Anti-connective tissue growth factor (CTGF) mAb | NCT03941093 |
| OMP-54F28 Ipafricept [624] | Decoy receptor for Wnt ligands. Anti-cancer stem cell | NCT02050178 |
| Vantictumab | Wnt signaling inhibitor mAb, by targeting frizzled receptors | NCT02005315 |
| Erlotinib | EGFR inhibitor | NCT01505413 |
| iNeo-Vac-P01 [625] | Personalized neo-antigen vaccine | NCT03645148 |
| LSL-161 [626] | IAP inhibitor | NCT01934634 |
| MK0752 | Notch signaling inhibitor | NCT01098344 |
| Gefitinib | EGFR inhibitor | NCT00234416 |
| Camrelizumab | Immune checkpoint inhibitor | NCT04498689 |
| PBP 1510 [627] | Monoclonal antibody directed against the expression of the oncogene PAUF | NCT05141149 |
| RAV12 [628] | mAb that recognizes an N-linked carbohydrate antigen (RAAG12) expressedin some tumors | NCT00625586 |
| Bevacizumab | Anti-angiogenesis | NCT00460174 |
| Celecoxib | Cox 2 inhibitor | NCT00068432 |
| Enzalutamide | Non-steroidal antiandrogen | NCT02138383 |
| Masitinib | Tyrosine kinase inhibitor anti PDGFR | NCT03766295 |
| Conatumumab | Monoclonal agonist antibody directed against the extracellular domain of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 | NCT01017822 |
| Bey 1107 | CDK1 inhibitor | NCT03579836 |
| MM-141 | Bispecific antibody against Erb B3 and IGF-IR | NCT02399137 |
| VX-671 | Serine proteinase inhibitor | NCT00499265 |
| Nivolumab | Immune checkpoint inhibitor | NCT04247165 |
| S-1 [629] | S-1 consists of three pharmacological agents -Tegafur, a prodrug of 5-FU; 5-Chloro-2-4-Dihydroxypyridine (CDHP), which inhibits the activity of Dihydropyrimidine Dehydrogenase (DPD); and Oxonic Acid (Oxo), which reduces gastrointestinal toxicity of 5-FU |
NCT00429858 |
| Lapatinib | EGFR inhibitor | NCT00447122 |
| ABTL0812 [630] | Increases cellular long-chain dihydroceramides which results in sustained ER stress and induces cytotoxic autophagy | NCT03417921 |
| Mirtazapine | Antidepressant | NCT01598584 |
| Simvastatin | Mevalonate pathway inhibitor | NCT00944463 |
| Etoposid | Topoisomerase II inhibitor | NCT00202800 |
| AZD0530 (saracatinib) | Src-Abl inhibitor | NCT00265876 |
| Methyl bardoxolone | Activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway | NCT00529113 |
| Tislelizumab | Anti-PD1 monoclonal antibody | NCT04902261 |
| TBI 1401 | Spontaneously attenuated mutant of herpes simplex virus type 1 | NCT03252808 |
| ARQ-761 | Β-lapachone analogue that causes massive oxidative stress | NCT02514031 |
| GV-1001 | Vaccine used foractive immunotherapy of cancers expressing telomerase | NCT02854072 |
| Triapine [631,632,633] | Ribonucleotide reductase inhibitor | NCT00064051 |
| Hua-Chan-Su | Traditional Chinese medicine extract from parotid gland of bufo toads | NCT00837239 |
| Tacedinaline | Histone deacetylase inhibitor | NCT00004861 |
| Icotinib | EGFR tyrosine kinase inhibitor | NCT02278458 |
| Imatinib | Tyrosine kinase inhibitor | NCT00161213 |
| Cabozantinib | Inhibitor of the tyrosine kinases c-Met and VEGFR2 | NCT01663272 |
| Ganitumab [634] (AMG 479) |
Human monoclonal antibody against IGF-IR | NCT01298401 NCT01318642 |
| IMPRIME PGG BTH1704 [635] |
PGG beta glucan is a soluble glucan that binds complement CR3 priming immune cells against opsonized tumor cells. BTH1704 is an Anti MUC1 antibody that binds modified extracellular MUC1 |
NCT02132403 |
| SLC 0111 [636] | Carbonic anhydrase IX selective inhibitor | NCT03450018 |
| SRF 617 [637] | Blocks CD39 preventing ATP degradation in the extracellular matrix, reducing adenosine and converting an immunosuppressive TME to a proinflammatory environment | NCT04336098 |
| Tislelizumab | PD-1 inhibitor | NCT04902261 |